Enhancing ventricular remodeling and cardiac function in post-acute myocardial infarction with sacubitril/valsartan

OBJECTIVE: To evaluate the therapeutic effect of sacubitril/valsartan compared to enalapril in managing heart failure (HF) after percutaneous coronary intervention (PCI). METHODS: From January 2018 to December 2021, 63 hospitalized patients diagnosed with HF following acute myocardial infarction (AMI) were enrolled in this prospective clinical trial. The observation group was comprised of 31 patients treated with sacubitril/valsartan (LCZ696) sodium tablets, while the control group, including 32 patients, received enalapril maleate tablets. All patients received standard HF therapy, including water-soluble aspirin, hydroclopidogrel sulfate, once-daily bivalirudin calcium, twice-daily metoprolol tartrate (dose titrated based on heart rate), once-daily spironolactone (dose adjusted for electrolytes), and once-daily dehydroimidazole (dose adjusted for electrolytes). HF symptom control, N-terminal B-type natriuretic peptide precursor (NT-proBNP) levels, cardiac anatomical parameters, heart rate, blood pressure, and 6-minute walking distance over a 90-day follow-up were assessed. The study is registered under ClinicalTrials.gov [ChiCTR2100042944]. RESULTS: On the 30th day post-discharge, the observation group exhibited a marked decrease in NT-proBNP levels and an improvement in left ventricular end-diastolic diameter, in contrast to the control group (both P<0.05). By the 90th day, the observation group showed significant improvements in left ventricular ejection fraction and left ventricular end-systolic diameter index, along with reduced blood pressure and serum creatinine levels (all P<0.05). Furthermore, the observation group displayed a more favorable New York Heart Association class distribution and enhanced performance in the 6-minute walk test (both P<0.05). No significant difference in the incidence of major adverse cardiovascular events was observed between the two groups during the 90-day follow-up period (P>0.05). CONCLUSION: Our findings indicate that sacubitril/valsartan (LCZ696) Sodium Tablets effectively enhance ventricular remodeling and cardiac function in patients with HF post-AMI, following a short-term treatment regimen. This therapeutic approach holds promise for improving clinical outcomes in this patient population.

Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.

El resumen se deja sin traducir para conservar la redacción original de los autores.

To evaluate the therapeutic effect of sacubitril/valsartan compared to enalapril in managing heart failure (HF) after percutaneous coronary intervention (PCI). From January 2018 to December 2021, 63 hospitalized patients diagnosed with HF following acute myocardial infarction (AMI) were enrolled in this prospective clinical trial.

Explore cómo esta investigación se conecta con la práctica clínica

Más estudios revisados por pares en la categoría «Seguridad y control de infecciones».

• Mejora de la atención al paciente mediante la hirudoterapia y la gestión de las sanguijuelas desde su recepción hasta su eliminación en Francia — Vaesken C et al. (2023)
• Hirudoterapia (sanguijuelas medicinales) para el tratamiento de la obstrucción de la vía aérea superior en un perro — Trenholme H, Masseau I, Reinero C (2021)
• Análisis de infecciones resistentes a antibióticos asociadas a la hirudoterapia — Brauer P et al. (2024)
• Síndrome de Kounis por hirudoterapia (terapia con sanguijuelas) en el servicio de urgencias; informe de un caso — Çakmak T et al. (2018)
• Complicaciones de la terapia con sanguijuelas — Pourrahimi M, Abdi M, Ghods R (2020)
• Terapia con sanguijuelas medicinales e infección por Aeromonas spp. — Verriere B et al. (2016)
• Replanteamiento de la profilaxis antimicrobiana en pacientes que reciben terapia con sanguijuelas medicinales — McCracken J, Koehler S, Sharma R (2022)
• Uso profiláctico de levofloxacino durante la terapia con sanguijuelas medicinales — Bauters T et al. (2014)
• Hemorragia digestiva alta relacionada con la aplicación de sanguijuelas: caso clínico — Dolek U et al. (2023)
• Un ensayo clínico para evaluar la aplicación de sanguijuelas en el manejo de la vicarcikā (eccema) — Shankar K et al. (2014)

Ver toda la investigación analizada por la ASH →